Drug intelligence / Profile preview

AIK-5

Development stage: Preclinical
Lead developer: Allinky Biopharma
Modality: Small Molecules
Administration: Oral

Overview

AIK-5 is a small molecule therapeutic drug developed by Allinky Biopharma SL. It functions as an allosteric inhibitor of Calcineurin (CaN) and Nuclear Factor of Activated T-cells cytoplasmic 1 (NFATC1). By inhibiting these key proteins, AIK-5 aims to suppress T-cell activation and the subsequent expression of pro-inflammatory genes. This mechanism of action positions AIK-5 as a potential treatment for immune system diseases and other related conditions.

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on AIK-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIK-5.

Explore the full profile